Delcath ocular melanoma drug-device combo too risky, panel says
This article was originally published in Clinica
Executive Summary
Shares of Delcath Systems lost half their value in after-hours trading on 2 May after the company's metastatic ocular melanoma drug-device treatment Melblez Kit (melphalan) was rejected by unanimous vote by a federal panel of advisers to the US FDA.